LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
Sponsored by Meril
Interventions for Valvular Disease
TAVI
Symposium
Meril
Room 241
Anchorperson: Andreas Baumbach
Spokesperson: Patrick Serruys
Discussants: Marie-Claude Morice, Vlasis Ninios, Marcin Protasiewicz, Daniel Unic
Speakers: Ignacio J Amat-Santos, Francesco Bedogni, Matjaz Bunc, Fausto Feres, Martin Hudec, Axel Linke, Yoshinobu Onuma, Osama Soliman, Niels Van Royen
Watch this session if you want
- To learn more about the first randomised trial that will report long-term (10 years) head-to-head outcomes to prove the non-inferiority of newer generation balloon-expandable Myval transcatheter heart valve series with commercially available contemporary TAVI devices (Sapien and Evolut transcatheter heart valve series)
- To check 30-day composite endpoint based on the Valve Academic Research Consortium-3 consensus
Session objectives
Patrick Serruys
LANDMARK trial
Andreas Baumbach
Is the LANDMARK trial a contemporary trial? - A close look at the baseline characteristics
Niels Van Royen
Importance of intermediate size as recommended by multi slice CT scan
Ignacio J Amat-Santos
Discussion and audience interaction
Matjaz Bunc
Real-world representative cases from LANDMARK RCT
Fausto Feres
Insight from quantitative aortography at procedure and echocardiography at predischarge and thirty days
Osama Soliman
Why and how the conductance disturbances were treated
Yoshinobu Onuma
Added value of Myval THV series to our practice
Patrick Serruys
Discussion and audience interaction
Session evaluation and key learnings
Patrick Serruys
